THE BEGINNING OF END OF HIV?

HIV / AIDS   still presents   a   challenge   that is  not   novel  to   Kenya,  Africa  and  the  world  at  a  whole.   Pre-exposure  prophylaxis   has  been  used  widely   in  the  last  few  years and  advanced  pharma  technology   is  still  keen  in  eradicating    the  disease  and  or  minimising  its  effects.

The Kenyan government will next month roll out a new drug meant to protect HIV-negative people from contracting the virus.   This is  a  drug   whose  clinlcal trials   may  have  been  recently  concluded  and    and  therefore  the  pharmacovigilance  part of  it  is  highly   in  its  prime  steps.

Pre-exposure Prophylaxis (PrEP) will be given to those at high risk of contracting the virus before being made accessible to the general public.  Pilot studies conducted in Kenya and Uganda showed that if taken once daily, the drugs can prevent HIV infection by more than 96 %..The drug is taken before exposure to risk of infection. To build adequate protection, people will need to take one pill daily for seven days.

PrEP1_1200px

TRUVADA   IS  MADE   OF   emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg)

Apart  from  the  general  public,  most  populations  of    concern    are  discordant couples, where the HIV-negative partner can be put on the drug, people with multiple sexual partners, individuals who have had sexually transmitted infections (STIs), people who inject drugs, people who have had recurrent use of post-exposure prophylaxis (PEP), sex workers and those who do not use condoms consistently.

2_1-how-to-take-truvada-img-TP

Speaking while announcing the roll-out, ‎the head of National AIDS and STI Control Program Dr Martin Sirengo said the drug has been included in the current HIV prevention methods.

A  combination of  PrEP  and  other   protection  mechanisms  include  use  of  condoms,  regular   tests  and  responsible  relationships i.e  one  sexual partner  at a  time.  In 2016, the government introduced PrEP, becoming the second country in sub-Saharan Africa after South Africa to issue full regulatory approval of the method, which uses antiretroviral drugs to protect HIV-negative people from getting infected.

Get more from     ELIZABETH MERAB

TRUVADA.COM

BY  SAMMERION NYAWARA.

 

KUPHSA

Leave a comment

  • Our Mission

    KUPHSA

    To Inspire Students Of Pharmacy To Believe In Themselves And Their Abilities, Work As A Team In Improving Healthcare And Create New Experiences While Defining Their Role In The Pharmaceutical Industry.